Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Total Current Liabilities for 7 consecutive years, with $12.0 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities changed 0.21% year-over-year to $12.0 million; the TTM value through Mar 2026 reached $12.0 million, changed 0.21%, while the annual FY2025 figure was $10.0 million, 36.02% down from the prior year.
  • Total Current Liabilities hit $12.0 million in Q1 2026 for Barinthus Biotherapeutics, up from $10.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.6 million in Q3 2023 and bottomed at $10.0 million in Q4 2025.
  • Average Total Current Liabilities over 5 years is $13.3 million, with a median of $12.6 million recorded in 2023.
  • Year-over-year, Total Current Liabilities soared 120.2% in 2022 and then tumbled 36.02% in 2025.
  • Barinthus Biotherapeutics' Total Current Liabilities stood at $12.2 million in 2022, then rose by 2.91% to $12.6 million in 2023, then increased by 24.28% to $15.7 million in 2024, then crashed by 36.02% to $10.0 million in 2025, then rose by 19.79% to $12.0 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $12.0 million, $10.0 million, and $10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.